Savitz Ryan 4
4 · Dianthus Therapeutics, Inc. /DE/ · Filed Sep 11, 2025
Insider Transaction Report
Form 4
Savitz Ryan
EVP, CFO & CBO
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2025-09-09+20,000→ 104,766 totalExercise: $8.44Exp: 2032-06-06→ Common Stock (20,000 underlying) - Exercise/Conversion
Common Stock
2025-09-09$8.44/sh+20,000$168,800→ 20,000 total - Sale
Common Stock
2025-09-09$35.00/sh−20,000$700,000→ 0 total
Footnotes (2)
- [F1]The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2025.
- [F2]The shares of common stock underlying this stock option award vested as to 25% of the shares on June 2, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.